CIDP

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune-mediated demyelinating neuropathy that has the potential to cause long-term disability. Timely identification and initiation of therapy are crucial to prevent people with CIDP developing long-term disability and neural damage.

How prevalent is CIDP?

The observed prevalence of CIDP is estimated to be 0.7–10.3 cases per 100,000 people.

Who is more at risk?

CIDP is more common in males, with a female-to-male ratio of 1.5:4.

What treatment options exist for CIDP?

Guidelines recommend a number of different treatment options for induction and maintenance in people with CIDP or suspected CIDP. However, many of these treatment options are off-label.

What condition is most commonly confused with CIDP?

Guillain–Barré syndrome is the leading alternative diagnosis for CIDP.

How does CIDP impact those with the disorder?

Beyond physical disability, people with CIDP can also experience a negative impact on social interaction and mental health. Difficulties with work, daily tasks, leisure activities, and dependency are common social functioning issues, often associated with physical disability.

Developed by EPG Health for Medthority, independently of any sponsor.